A citation-based method for searching scientific literature

Michael Brownlee. Diabetes 2005
Times Cited: 3045







List of co-cited articles
486 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Oxidative stress and diabetic complications.
Ferdinando Giacco, Michael Brownlee. Circ Res 2010
17

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
12

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
8

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
8

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi, Inga Petersohn, Paraskevi Salpea, Belma Malanda, Suvi Karuranga, Nigel Unwin, Stephen Colagiuri, Leonor Guariguata, Ayesha A Motala, Katherine Ogurtsova,[...]. Diabetes Res Clin Pract 2019
8

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
7



Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells.
Xueliang Du, Takeshi Matsumura, Diane Edelstein, Luciano Rossetti, Zsuzsanna Zsengellér, Csaba Szabó, Michael Brownlee. J Clin Invest 2003
530
6

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
5

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
5

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.
T Nishikawa, D Edelstein, X L Du, S Yamagishi, T Matsumura, Y Kaneda, M A Yorek, D Beebe, P J Oates, H P Hammes,[...]. Nature 2000
5

Mechanisms of diabetic complications.
Josephine M Forbes, Mark E Cooper. Physiol Rev 2013
5

Effect of a multifactorial intervention on mortality in type 2 diabetes.
Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2008
5


The progress in understanding and treatment of diabetic retinopathy.
Alan W Stitt, Timothy M Curtis, Mei Chen, Reinhold J Medina, Gareth J McKay, Alicia Jenkins, Thomas A Gardiner, Timothy J Lyons, Hans-Peter Hammes, Rafael Simó,[...]. Prog Retin Eye Res 2016
348
5

Advanced glycation end products and diabetic complications.
Varun Parkash Singh, Anjana Bali, Nirmal Singh, Amteshwar Singh Jaggi. Korean J Physiol Pharmacol 2014
554
4

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
Louis Monnier, Emilie Mas, Christine Ginet, Françoise Michel, Laetitia Villon, Jean-Paul Cristol, Claude Colette. JAMA 2006
4

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
634
4

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
4

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
4

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
700
4

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
4

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
4

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
4

Contribution of polyol pathway to diabetes-induced oxidative stress.
Stephen S M Chung, Eric C M Ho, Karen S L Lam, Sookja K Chung. J Am Soc Nephrol 2003
324
4

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
4

Cellular death, reactive oxygen species (ROS) and diabetic complications.
Caroline Maria Oliveira Volpe, Pedro Henrique Villar-Delfino, Paula Martins Ferreira Dos Anjos, José Augusto Nogueira-Machado. Cell Death Dis 2018
325
4

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
Peter Gaede, Pernille Vedel, Nicolai Larsen, Gunnar V H Jensen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2003
4

Glucose control and vascular complications in veterans with type 2 diabetes.
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
4

Diabetes, oxidative stress, and antioxidants: a review.
A C Maritim, R A Sanders, J B Watkins. J Biochem Mol Toxicol 2003
4

Reduction of renal superoxide dismutase in progressive diabetic nephropathy.
Hiroki Fujita, Hiromi Fujishima, Shinsuke Chida, Keiko Takahashi, Zhonghua Qi, Yukiko Kanetsuna, Matthew D Breyer, Raymond C Harris, Yuichiro Yamada, Takamune Takahashi. J Am Soc Nephrol 2009
109
4


Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.
Kerstin Nowotny, Tobias Jung, Annika Höhn, Daniela Weber, Tilman Grune. Biomolecules 2015
407
3

Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.
Mary Elizabeth Patti, Atul J Butte, Sarah Crunkhorn, Kenneth Cusi, Rachele Berria, Sangeeta Kashyap, Yoshinori Miyazaki, Isaac Kohane, Maura Costello, Robert Saccone,[...]. Proc Natl Acad Sci U S A 2003
3

Reactive oxygen species have a causal role in multiple forms of insulin resistance.
Nicholas Houstis, Evan D Rosen, Eric S Lander. Nature 2006
3

A new equation to estimate glomerular filtration rate.
Andrew S Levey, Lesley A Stevens, Christopher H Schmid, Yaping Lucy Zhang, Alejandro F Castro, Harold I Feldman, John W Kusek, Paul Eggers, Frederick Van Lente, Tom Greene,[...]. Ann Intern Med 2009
3

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients.
Antonio Ceriello, Katherine Esposito, Ludovica Piconi, Michael A Ihnat, Jessica E Thorpe, Roberto Testa, Massimo Boemi, Dario Giugliano. Diabetes 2008
723
3

Diabetes mellitus, fasting glucose, and risk of cause-specific death.
Sreenivasa Rao Kondapally Seshasai, Stephen Kaptoge, Alexander Thompson, Emanuele Di Angelantonio, Pei Gao, Nadeem Sarwar, Peter H Whincup, Kenneth J Mukamal, Richard F Gillum, Ingar Holme,[...]. N Engl J Med 2011
3

Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy.
L Monnier, C Colette, E Mas, F Michel, J P Cristol, C Boegner, D R Owens. Diabetologia 2010
100
3

The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c.
Feng Xu, Li-Hua Zhao, Jian-Bin Su, Tong Chen, Xue-Qin Wang, Jin-Feng Chen, Gang Wu, Yan Jin, Xiao-Hua Wang. Diabetol Metab Syndr 2014
64
4

Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited.
John M Lachin, Saul Genuth, David M Nathan, Bernard Zinman, Brandy N Rutledge. Diabetes 2008
287
3

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
829
3

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
3

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
3

The changing face of diabetes complications.
Edward W Gregg, Naveed Sattar, Mohammed K Ali. Lancet Diabetes Endocrinol 2016
194
3

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
3

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
448
3

Severe hypoglycemia and risks of vascular events and death.
Sophia Zoungas, Anushka Patel, John Chalmers, Bastiaan E de Galan, Qiang Li, Laurent Billot, Mark Woodward, Toshiharu Ninomiya, Bruce Neal, Stephen MacMahon,[...]. N Engl J Med 2010
945
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.